To qualify for Wegovy, youll typically need one of the following: A BMI of 30 or higher (classified as obesity ), or A BMI of 27 or higher with at least one weight-related health condition Weight-related conditions may include: High blood pressure (hypertension) High cholesterol (dyslipidemia) Type 2 diabetes Heart disease Obstructive sleep apnea Polycystic ovary syndrome ( PCOS ) In addition, in March 2024 the FDA expanded Wegovys approval to include reducing the risk of major cardiovascular events like heart attac k, stroke, and cardiovascular death in adults with cardiovascular disease plus overweight or obesity
Dashti S, Eftekhar M
Targeting the GLP-1/GLP-1R axis to treat osteoarthritis: A new opportunity
States which previously had coverage such as California, New Hampshire, Pennsylvania and South Carolina have also eliminated GLP-1 coverage for weight loss in recent months
Other routes occasionally mentioned include intramuscular injection and, less commonly, intranasal or topical formulations
The Importance of Medical Supervision and Personalized Care Mounjaros efficacy and safety depend greatly on appropriate patient selection, dosing, and monitoringhighlighting the value of medically supervised weight loss programs